Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 78

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 78
---
 Termination, due to the following:

•

Liminatus’s licensing partnership with InnoBation, a biotechnology company headquartered in the Republic of Korea, specializing in cancer therapies. Through this partnership, Liminatus gains access to InnoBation’s anti-CD47 technology, a promising asset in the fight against cancer.

•

Extensive clinical studies have highlighted CD47 as a compelling target for drug development across a broad range of cancers. Liminatus is well positioned in immuno-oncology, leveraging its differentiated anti-CD47 monoclonal antibody, which is specifically designed to address significant challenges observed in earlier CD47 therapies, such as anemia.

•

The global market for CD47-targeted therapies continues to exhibit significant demand, particularly as these inhibitors gain traction in combination with established PD-1/PD-L1 blockades, a market projected to exceed $123 billion by 2033. Liminatus’s innovative approach and intellectual property rights make it well-suited to capture a significant share of this growing market.

•

Furthermore, advances in research since the Business Combination Agreement was initially signed have strengthened the value proposition of the CD47 asset. Critical preclinical work, including CMC development and toxicity studies, has been completed, alongside independent research revealing potential new applications for the CD47 asset in mitigating age-related diseases, such as cardiovascular disease and obesity. These developments highlight CD47’s broad therapeutic potential, reinforcing the Business Combination’s importance and long-term value for stockholders.

In the course of its deliberations, in addition to the various other risks associated with the business of Liminatus, as described in the section titled “ Risk Factors ” appearing elsewhere in this proxy statement/ prospectus, the Iris Board also considered a variety of uncertainties, risks, and other potentially negative factors relevant to the Business Combination, including the following:

•

Macroeconomic uncertainty, including with respect to global and national supply chains, and the effects they could have on Liminatus’s revenues and financial performance.

•

The risk that Liminatus may not be able to execute on its business plan and realize its anticipated financial performance.

•

The risk that Liminatus’s products in development do not perform as expected, fail clinical trials, or are not approved by the U.S. Food and Drug Administration (“FDA”) or other applicable regulatory authorities .

•

Clinical trials are long and expensive, and the results of such are uncertain.

•

Liminatus is subject to continuing regulatory compliance by the FDA and other applicable regulatory authorities, which could result in negative effects